The US Food & Drug Administration’s rejection of a broader label for Alnylam Pharmaceuticals Inc.’s Onpattro (patisiran) is yet another reminder of the surprising intricacies of product assessments at the agency.
Less than a month ago, the Cardio-Renal Drugs Advisory Committee voted 9-3 that the benefits of the drug for use in AATR-associated cardiomyopathy outweighed the risks. The committee’s enthusiasm for the efficacy of Onpattro was lukewarm at best – but the vote was still a noteworthy endorsement given the bluntly negative FDA review of the data presented during the meeting
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?